Connect with us

Health

Prostate Cancer: Over-Testing and Over-Treatment

Published

9 minute read

From the Brownstone Institute

By Bruce W. Davidson 

The excessive medical response to the Covid pandemic made one thing abundantly clear: Medical consumers really ought to do their own research into the health issues that impact them. Furthermore, it is no longer enough simply to seek out a “second opinion” or even a “third opinion” from doctors. They may well all be misinformed or biased. Furthermore, this problem appears to predate the Covid phenomenon.

A striking example of that can be found in the recent history of prostate cancer testing and treatment, which, for personal reasons, has become a subject of interest to me. In many ways, it strongly resembles the Covid calamity, where misuse of the PCR test resulted in harming the supposedly Covid-infected with destructive treatments.

Two excellent books on the subject illuminate the issues involved in prostate cancer. One is Invasion of the Prostate Snatchers by Dr. Mark Scholz and Ralph Blum. Dr. Scholtz is executive director of the Prostate Cancer Research Institute in California. The other is The Great Prostate Hoax by Richard Ablin and Ronald Piana. Richard Ablin is a pathologist who invented the PSA test but has become a vociferous critic of its widespread use as a diagnostic tool for prostate cancer.

Mandatory yearly PSA testing at many institutions opened up a gold mine for urologists, who were able to perform lucrative biopsies and prostatectomies on patients who had PSA test numbers above a certain level. However, Ablin has insisted that “routine PSA screening does far more harm to men than good.” Moreover, he maintains that the medical people involved in prostate screening and treatment represent “a self-perpetuating industry that has maimed millions of American men.”

Even during approval hearings for the PSA test, the FDA was well aware of the problems and dangers. For one thing, the test has a 78% false positive rate. An elevated PSA level can be caused by various factors besides cancer, so it is not really a test for prostate cancer. Moreover, a PSA test score can spur frightened men into getting unnecessary biopsies and harmful surgical procedures.

One person who understood the potential dangers of the test well was the chairman of the FDA’s committee, Dr. Harold Markovitz, who decided whether to approve it. He declared, “I’m afraid of this test. If it is approved, it comes out with the imprimatur of the committee…as pointed out, you can’t wash your hands of guilt. . .all this does is threaten a whole lot of men with prostate biopsy…it’s dangerous.”

In the end, the committee did not give unqualified approval to the PSA test but only approved it “with conditions.” However, subsequently, the conditions were ignored.

Nevertheless, the PSA test became celebrated as the route to salvation from prostate cancer. The Postal Service even circulated a stamp promoting yearly PSA tests in 1999. Quite a few people became wealthy and well-known at the Hybritech company, thanks to the Tandem-R PSA test, their most lucrative product.

In those days, the corrupting influence of the pharmaceutical companies on the medical device and drug approval process was already apparent. In an editorial for the Journal of the American Medical Association (quoted in Albin and Piana’s book), Dr. Marcia Angell wrote, “The pharmaceutical industry has gained unprecedented control over the evaluation of its products…there’s mounting evidence that they skew the research they sponsor to make their drugs look better and safer.” She also authored the book The Truth About the Drug Companies: How They Deceive Us and What to Do About It.

A cancer diagnosis often causes great anxiety, but in actuality, prostate cancer develops very slowly compared to other cancers and does not often pose an imminent threat to life. A chart featured in Scholz and Blum’s book compares the average length of life of people whose cancer returns after surgery. In the case of colon cancer, they live on average two more years, but prostate cancer patients live another 18.5 years.

In the overwhelming majority of cases, prostate cancer patients do not die from it but rather from something else, whether they are treated for it or not. In a 2023 article about this issue titled “To Treat or Not to Treat,” the author reports the results of a 15-year study of prostate cancer patients in the New England Journal of Medicine. Only 3% of the men in the study died of prostate cancer, and getting radiation or surgery for it did not seem to offer much statistical benefit over “active surveillance.”

Dr. Scholz confirms this, writing that “studies indicate that these treatments [radiation and surgery] reduce mortality in men with Low and Intermediate-Risk disease by only 1% to 2% and by less than 10% in men with High-Risk disease.”

Nowadays prostate surgery is a dangerous treatment choice, but it is still widely recommended by doctors, especially in Japan. Sadly, it also seems to be unnecessary. One study cited in Ablin and Piana’s book concluded that “PSA mass screening resulted in a huge increase in the number of radical prostatectomies. There is little evidence for improved survival outcomes in the recent years…”

However, a number of urologists urge their patients not to wait to get prostate surgery, threatening them with imminent death if they do not. Ralph Blum, a prostate cancer patient, was told by one urologist, “Without surgery you’ll be dead in two years.” Many will recall that similar death threats were also a common feature of Covid mRNA-injection promotion.

Weighing against prostate surgery are various risks, including death and long-term impairment, since it is a very difficult procedure, even with newer robotic technology. According to Dr. Scholz, about 1 in 600 prostate surgeries result in the death of the patient. Much higher percentages suffer from incontinence (15% to 20%) and impotence after surgery. The psychological impact of these side effects is not a minor problem for many men.

In light of the significant risks and little proven benefit of treatment, Dr. Scholz censures “the urology world’s persistent overtreatment mindset.” Clearly, excessive PSA screening led to inflicting unnecessary suffering on many men. More recently, the Covid phenomenon has been an even more dramatic case of medical overkill.

Ablin and Piana’s book makes an observation that also sheds a harsh light on the Covid medical response: “Isn’t cutting edge innovation that brings new medical technology to the market a good thing for health-care consumers? The answer is yes, but only if new technologies entering the market have proven benefit over the ones they replace.”

That last point especially applies to Japan right now, where people are being urged to receive the next-generation mRNA innovation–the self-amplifying mRNA Covid vaccine. Thankfully, a number seem to be resisting this time.

Author

Bruce Davidson is professor of humanities at Hokusei Gakuen University in Sapporo, Japan.

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

Business

Kennedy to cut 10,000 HHS employees to reduce ‘bureaucratic sprawl’

Published on

From The Center Square

By 

The changes are expected to reduce the agency’s headcount from 82,000 to 62,000 full-time employees.

Robert F. Kennedy Jr. announced a significant restructuring of the U.S. Department of Health and Human Services on Thursday in a move to streamline the huge federal agency and cut costs.

Kennedy plans to trim about 10,000 employees from the agency’s workforce in addition to employees who left as part of a Deferred Resignation Program, similar to a buy out, earlier this year. The move is expected to save about $1.8 billion.

Kennedy said the restructuring won’t affect the agency’s critical services. When combined with HHS’ other efforts, including early retirement, the changes are expected to reduce the agency’s headcount from 82,000 to 62,000 full-time employees. The restructuring will also align the department with Kennedy’s goals for a healthier U.S. population.

“We aren’t just reducing bureaucratic sprawl. We are realigning the organization with its core mission and our new priorities in reversing the chronic disease epidemic,” Kennedy said. “This Department will do more – a lot more – at a lower cost to the taxpayer.”

Kennedy also said the restructuring of the department’s 28 divisions will get rid of redundant units, consolidating them into “15 new divisions, including a new Administration for a Healthy America, or AHA, and will centralize core functions such as Human Resources, Information Technology, Procurement, External Affairs, and Policy.” Regional offices will be reduced from 10 to 5.

The overhaul will implement the new “HHS priority of ending America’s epidemic of chronic illness by focusing on safe, wholesome food, clean water, and the elimination of environmental toxins. These priorities will be reflected in the reorganization of HHS.”

Kennedy also said the restructuring would improve taxpayers’ experience with HHS by making the agency more responsive and efficient. He also said the changes would ensure that Medicare, Medicaid, and other essential health services remain intact.

The Administration for a Healthy America will combine multiple agencies – the Office of the Assistant Secretary for Health, Health Resources and Services Administration, Substance Abuse and Mental Health Services Administration, Agency for Toxic Substances and Disease Registry, and National Institute for Occupational Safety and Health — into a single, unified entity, Kennedy said.

The Centers for Disease Control and Prevention will get the Administration for Strategic Preparedness and Response, which is responsible for national disaster and public health emergency response.

“Over time, bureaucracies like HHS become wasteful and inefficient even when most of their staff are dedicated and competent civil servants,” Kennedy said. “This overhaul will be a win-win for taxpayers and for those that HHS serves.”

Among the cuts: The U.S. Food and Drug Administration will shed about 3,500 full-time employees. Officials said the reduction won’t affect drug, medical device, or food reviewers, nor will it impact inspectors. The CDC will drop about 2,400 employees. The National Institutes of Health will cut about 1,200 employees. The Centers for Medicare & Medicaid Services will cut about 300 employees. The reorganization won’t affect Medicare and Medicaid services, officials said.

Continue Reading

Health

How the once-blacklisted Dr. Jay Bhattacharya could help save healthcare

Published on

From LifeSiteNews

By Christina Maas

Now seated at the helm of the National Institutes of Health, Dr. Jay Bhattacharya is poised to reshape not only the agency’s research priorities but the very culture that pushed him to the fringe.

Imagine spending your career studying infectious diseases, only to find that the real virus spreading uncontrollably is censorship. That was the reality for Dr. Jay Bhattacharya, a Stanford epidemiologist who committed the unpardonable sin of questioning the COVID-19 lockdown orthodoxy. His punishment? Digital exile, courtesy of Silicon Valley’s Ministry of Truth.

In December 2022, the Twitter Files exposed what many had long suspected: Twitter had quietly placed Bhattacharya’s account on a Trends Blacklist. This ensured that his posts, often critical of lockdowns and mask mandates, would never see the light of day on the platform’s trending topics. In other words, Twitter’s algorithm worked like a digital bouncer, making sure his dissenting opinions never made it past the velvet rope.

And Twitter wasn’t alone. Facebook, ever eager to please its government handlers, scrubbed the Great Barrington Declaration from its pages. That document, co-authored by Bhattacharya and other esteemed scientists, dared to suggest that maybe, just maybe, locking down entire populations wasn’t the best strategy. Instead, it proposed focused protection for the most vulnerable while allowing the rest of society to function. For this, it was sent to the digital equivalent of a gulag.

These experiences took center stage during Bhattacharya’s Senate confirmation hearing for the directorship of the National Institutes of Health (NIH). Republican lawmakers, who suddenly found themselves cast as the last defenders of free speech in scientific discourse, saw his nomination as a win.

During his testimony, Bhattacharya didn’t mince words. He detailed how the Biden administration played an active role in orchestrating the suppression of alternative views. It wasn’t enough for officials to push their own pandemic policies — they needed to ensure that no one, regardless of expertise, could challenge them in the public square.

The Science™ vs. The Science

Bhattacharya’s testimony laid bare an uncomfortable truth: the pandemic was a crisis of speech. “The root problem was that people who had alternative ideas were suppressed,” he told Sen. Ashley Moody (R-Fla.). “I personally was subject to censorship by the actions of the Biden administration during the pandemic.”

In a functioning society, that statement would spark bipartisan outrage. Instead, it barely registered. The people who spent years chanting “trust the science” were never interested in science at all.

Real science thrives on debate, skepticism, and the understanding that no single expert — no matter how credentialed—holds absolute truth. But during COVID, science became The Science™ — a government-approved doctrine enforced by Silicon Valley moderators and federal bureaucrats. Deviate from it, and you weren’t just wrong. You were dangerous.

A government-sanctioned muzzle

Bhattacharya wasn’t silenced in some haphazard, accidental way. The Biden administration actively leaned on social media companies to “moderate” voices like his. In practice, that meant tech executives — most of whom couldn’t tell a virus from a viral tweet — decided which epidemiologists the public was allowed to hear.

He responded with a lawsuit against the administration, accusing it of colluding with Big Tech to crush dissent. But in a ruling as predictable as it was revealing, the Supreme Court dismissed the case, arguing that Bhattacharya and his fellow plaintiffs lacked standing. Meaning: Yes, the government may have pressured private companies into silencing critics, but unless you can prove exactly how that harmed you, don’t expect the courts to care.

The real role of science

Despite everything, Bhattacharya didn’t argue for scientists to dictate policy. Unlike the public health bureaucrats who spent the pandemic issuing commandments from their Zoom thrones, he made it clear: “Science should be an engine for freedom,” he said. “Not something where it stands on top of society and says, ‘You must do this, this or this, or else.’”

That distinction matters. Science informs, but policy is about trade-offs. The problem wasn’t that officials got things wrong — it’s that they refused to admit the possibility. Instead of allowing open debate, they silenced critics. Instead of acknowledging uncertainty, they imposed rules with absolute certainty.

Bhattacharya wasn’t censored because he was wrong. He was censored because he questioned people who couldn’t afford to be.

His confirmation hearing made one thing clear: science wasn’t about data. It was about power. And in Washington, power doesn’t like to be questioned.

Science, money and power

At the heart of the hearing was a fundamental question: Who controls science that people are allowed to talk about? The NIH, with its $48 billion budget, is less a research institution and more a financial leviathan, shaping the direction of American science through the projects it funds (or doesn’t)  fund.

Bhattacharya’s nomination comes at a moment when the battle lines around scientific freedom, government intervention, and public trust in research are more entrenched than ever. The pandemic shattered the illusion that science was above politics. Instead, it exposed just how much political and corporate interests shape what counts as “settled” science.

The irony is thick enough to cut with a knife. The man once branded too dangerous for social media, blacklisted for questioning lockdowns, and effectively erased from mainstream discourse is now being handed a key role in the very government that tried to silence him. Dr. Jay Bhattacharya, once forced to the margins, is now at the center of power.

A new administration has decided that maybe — just maybe — silencing dissenting scientists wasn’t the best pandemic strategy. And in a twist no Hollywood scriptwriter would dare to pitch for being too on-the-nose, Bhattacharya wasn’t being welcomed back into the conversation — he’s being put in charge of it.

Bhattacharya was confirmed following a party-line vote Tuesday evening. The decision came after a similarly partisan endorsement from the Senate Committee on Health, Education, Labor and Pensions (HELP), clearing the final hurdle for President Donald Trump’s nominee.

Equally central to his testimony was Bhattacharya’s call for a sweeping shift in NIH priorities. He proposed a decentralization of research funding, stressing the need for greater inclusion of dissenting voices in the scientific process, an apparent rebuke of the consensus-driven culture that dominated during the pandemic. He emphasized targeting resources toward projects with a clear and measurable impact on public health, dismissing other NIH initiatives as “frivolous.”

Now seated at the helm of the National Institutes of Health, Dr. Jay Bhattacharya is poised to reshape not only the agency’s research priorities but the very culture that pushed him to the fringe. His confirmation, hard-won and unapologetically political, is already shaking the scaffolding of a scientific establishment that long equated conformity with consensus.

Reprinted with permission from Reclaim The Net

Continue Reading

Trending

X